Search results
Results from the WOW.Com Content Network
If a patient has the characteristic signs and symptoms of a pheochromocytoma and the decision is made to pursue additional biochemical (blood work) evaluation, the differential diagnosis is important as it is more likely to be something other than a pheochromocytoma given the relative frequency of 0.8 per 100,000 person-years.
Multiple endocrine neoplasia type 2 (also known as "Pheochromocytoma (codons 630 and 634) and amyloid producing medullary thyroid carcinoma", [1] "PTC syndrome," [1] and "Sipple syndrome" [1]) is a group of medical disorders associated with tumors of the endocrine system.
Blood test results should always be interpreted using the reference range provided by the laboratory that performed the test. ... 13–45 years: 0.7 [105] 20 [105 ...
For example, if the only presentation is a deviating laboratory parameter and all common harmful underlying conditions have been ruled out, then it may be acceptable to stop finding more candidate conditions, but this would much more likely be unacceptable if the presentation would have been severe pain.
They are used for laboratory quality control, in "runs" consisting of measurements of multiple samples. They are a set of modified Western Electric rules, developed by James Westgard and provided in his books and seminars on quality control. [1]
A complete blood count (CBC), also known as a full blood count (FBC), is a set of medical laboratory tests that provide information about the cells in a person's blood.The CBC indicates the counts of white blood cells, red blood cells and platelets, the concentration of hemoglobin, and the hematocrit (the volume percentage of red blood cells).
James D. Watson served as the Laboratory's director and president for 35 years. Upon taking charge in 1968, he focused the Laboratory on cancer research, creating a tumor virus group and successfully obtaining federal funds for an expansion of cancer research capabilities. Watson placed CSHL on a firm financial footing.
The BNF for Children developed from the British National Formulary (BNF), which prior to 2005 had provided information on the treatment of children, with the doses largely determined by calculations based on the body weight of the child. The guidance was provided by pharmacists and doctors whose expertise was in the care of adults.